Notable Runner: Achillion Pharmaceuticals, Inc.’s Trend Down, Especially After Today’s Weak Session

Notable Runner: Achillion Pharmaceuticals, Inc.'s Trend Down, Especially After Today's Weak Session

The stock of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) is a huge mover today! About 1.13M shares traded hands. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has risen 6.42% since March 8, 2016 and is uptrending. It has underperformed by 2.90% the S&P500.
The move comes after 7 months negative chart setup for the $1.05 billion company. It was reported on Oct, 11 by Barchart.com. We have $7.10 PT which if reached, will make NASDAQ:ACHN worth $63.00 million less.

Analysts await Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) to report earnings on November, 3. They expect $-0.17 EPS, down 230.77% or $0.30 from last year’s $0.13 per share. After $-0.14 actual EPS reported by Achillion Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 21.43% negative EPS growth.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Ratings Coverage

Out of 9 analysts covering Achillion Pharma (NASDAQ:ACHN), 6 rate it a “Buy”, 1 “Sell”, while 2 “Hold”. This means 67% are positive. Achillion Pharma has been the topic of 14 analyst reports since August 13, 2015 according to StockzIntelligence Inc. The firm earned “Outperform” rating on Friday, September 23 by Wedbush. Chardan Capital Markets initiated it with “Sell” rating and $4 target price in Thursday, July 14 report. The firm has “Market Perform” rating given on Friday, January 29 by Leerink Swann. Maxim Group maintained Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) on Thursday, February 25 with “Buy” rating. Maxim Group maintained it with “Buy” rating and $11 target price in Thursday, August 13 report. The stock has “Outperform” rating given by FBR Capital on Thursday, September 15. The rating was upgraded by JMP Securities to “Market Outperform” on Thursday, July 7. The company was initiated on Wednesday, September 9 by Jefferies. Chardan Capital Markets maintained the stock with “Sell” rating in Friday, September 23 report. The firm has “Outperform” rating by Robert W. Baird given on Friday, February 26.

According to Zacks Investment Research, “ACHILLION PHARMACEUTICALS, INC. is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The company’s proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease — HIV, hepatitis and resistant bacterial infections. Achillion sees significant competitive advantages in developing anti-infective drugs compared to developing drugs in other therapeutic areas. The emergence of drug resistance seen with current antiviral and antibacterial therapies creates a continuing need for new drugs, providing a large and growing potential business opportunity. In addition, development cycle times tend to be somewhat shorter in infectious disease than other therapeutic areas, and early drug development results tend to be more predictive of longer term results.”

Insitutional Activity: The institutional sentiment increased to 1 in Q2 2016. Its up 0.08, from 0.92 in 2016Q1. The ratio improved, as 21 funds sold all Achillion Pharmaceuticals, Inc. shares owned while 39 reduced positions. 12 funds bought stakes while 48 increased positions. They now own 107.31 million shares or 4.98% less from 112.94 million shares in 2016Q1.
Price T Rowe Assocs Md has 4.87M shares for 0.01% of their US portfolio. One Trading L P accumulated 45,643 shares or 0% of the stock. Blackrock, a New York-based fund reported 24,652 shares. Point72 Asset Mngmt L P accumulated 0.48% or 8.99M shares. Marshall Wace Llp holds 540,611 shares or 0.04% of its portfolio. New York State Common Retirement Fund holds 0% of its portfolio in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 127,700 shares. Cambridge Invest Research Advsr Inc has 0.01% invested in the company for 32,510 shares. Next Group has invested 0% of its portfolio in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Manufacturers Life The last reported 0% of its portfolio in the stock. Deutsche Bank & Trust Ag last reported 1.49 million shares in the company. Moreover, Balyasny Asset Management Ltd Liability Corp has 0% invested in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 23,100 shares. Metropolitan Life Ny last reported 83,260 shares in the company. Moreover, Hbk Invests L P has 0.01% invested in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 128,100 shares. Moreover, Blair William Il has 0% invested in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 37,400 shares. South Dakota Inv Council holds 670,600 shares or 0.11% of its portfolio.

Another recent and important Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) news was published by Courant.com which published an article titled: “With A Promising Hep C Drug, Achillion Looks To The Future” on September 29, 2016.

ACHN Company Profile

Achillion Pharmaceuticals, Inc., incorporated on August 5, 1998, is a biopharmaceutical company. The Company’s primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Firm is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system. The complement system is part of the body’s immune system. The Firm has initiated a first-in-human Phase I clinical trial for its first complement factor D inhibitor, ACH-4471, to assess safety, tolerability, pharmacokinetics, or PK, and pharmacodynamics, or PD.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment